.

o An immune-oncology company that has identified a novel receptor—

nfP2X7—that exists in a range of cancers, including lung, breast,

colorectal, and prostate tumors, but is not found on healthy tissue

- drugs directed to the nfP2X7 target may prove effective at

treating cancers with high precision and minimal side effects

o Biosceptre is progressing into pivotal clinical trials with a portfolio of

three anticancer compounds:

(1) BIL03s, a systemic domain antibody to treat blood-based and

solid cancers

(2) BIL06v, a peptide vaccine therapeutic that stimulates the patient’s

own immune system to target nfP2X7 in cancers

(3) BIL010t, a topical antibody treatment targeting nfP2X7 in non-

melanoma skin cancers

Crystal Research Associates Presents:

New Independent Equity Research

A 52-page Executive Informational Overview® (EIO) by Crystal Research Associates is

available on Biosceptre International Ltd. (closely held) at www.crystalra.com.

.

• Crystal clear, comprehensive report on a company in a manner that is

easily understood by the Wall Street financial community

• Product/technology/service offerings, market size(s), key intellectual

property, leadership, growth strategy, competition, risks, financial

statements, key events, and other fundamental information are detailed

• Free of investment ratings, target prices, and forward-looking financial

models

• Complete risks and disclosures

• Written exclusively by experienced, award-winning analysts

What is an EIO?

.

Overview of Biosceptre International (Closely Held)

• Significant R&D is underway in the area of targeted cancer therapies, as they are a cornerstone of precision

medicine. To date, over 30 monoclonal antibodies (mAbs), administered either alone or conjugated with a cytotoxic

agent, have been approved by the U.S. FDA to treat cancer.

- Currently available targeted therapies are sold at a high price, yet are often still associated with poor efficacy

and a relatively minor impact at improving quality of life. Should a new, targeted therapeutic prove effective

while demonstrating an excellent safety and efficacy profile, it could capture a significant share of a market

forecast to reach $125 billion by 2020.

• Biosceptre’s highly specific molecular target has been identified on the cell surface of 20+ human cancer tissue types.

• The Company holds 13 issued U.S. patent families as well as a global intellectual property (IP) portfolio that

offers protection out to 2032 and continues to file patent applications. This IP portfolio is believed to enable the

Company to pursue its multi-modality approach with freedom to operate.

• The team leading Biosceptre’s antibody development is experienced in commercial and research services as well as

in developing therapeutic antibodies for use in trials, de-risking scale-up.

• To continue developing its current oncology product candidates, Biosceptre seeks to raise £25 million (~US$32.8

million) via its first institutional financing event.

• The Company is headquartered at the Babraham Research Campus in Babraham, Cambridge (UK)

with offices also in Australia.

.

Experienced Leadership

• A team experienced in product development

• Chief Scientific Officer Dr. Shaun McNulty has over 20 years in major pharma and biotech drug discovery

• Scientific Advisory Board led by

(1) Sir Gregory Winter, a founder of Cambridge Antibody Technology, Domantis, and cofounder of Bicycle

Therapeutics

(2) Professor Terrence Rabbitts, a professor of molecular biology at the University of Oxford

• Clinicians supporting Biosceptre’s trials include

- Professor Gavin Marx (chair of the Section of Oncology at the Sydney Adventist Hospital [Aus.])

- Professor Nick Pavlakis (head of medical oncology, Royal North Shore [Aus.])

- Dr. Bob Li (attending physician at Memorial Sloan Kettering [U.S.]).

• CEO Gavin Currie has significant M&A experience

- Formerly general manager of Creata Ventures, a

family-held investment fund with a strong focus in

biotech

- Previously founded a boutique transaction services

company

Biosceptre’s corporate

headquarters in the Jonas

Webb Building in the UK

.

• nfP2X7 receptor has been shown by Biosceptre to be involved in the proliferation and survival of cancer cells

- It enables cancer cells to avoid experiencing ATP-induced apoptosis (regulated cell death under normal

conditions)

• nfP2X7 can be targeted on its own or in combination with other oncology therapeutics that act on other

biological pathways and targets

• Biosceptre has developed antibodies that precisely target nfP2X7 as it occurs on cancer cells

The Science Behind nfP2X7

PROPORTION OF CANCERS FOUND EXPRESSING NFP2X7*

Bla

dd

er

Bre

ast

Co

lon

Kid

ney

Lu

ng

Ovar i

an

Pro

sta

te

Test i

cu

lar

Sto

mach

Mela

no

ma

Pan

cre

at i

c

0

5 0

1 0 0

T u m o u r ty p e

% p

os

itiv

e s

tain

ing

P D X

T u m o u r b io p s y

8

6 5

3

9

5 8

5 4

1 3

1 2

1

6

1 2

6 6

1 3

5 07

3

1 82 4

4 6

Tumor type*Source: Biosceptre International.

.

Biosceptre’s Product Pipeline

CLINICAL PROGRAMS

DISCOVERY PROGRAMS

Approach Indication Discovery Preclinical Phase I Phase IIProduct

BIL06v

BIL010t

Next gen. systemic monoclonal

Next gen. peptide vaccine

Domain Ab Solid tumors

Peptide Vaccine

Topical dAbBIL011t

BIL04s

BIL07v

BIL03s

Solid tumors

Polyclonal Ab Basal cell carcinoma

BIL03n

BPM09

Conjugate candidate

IHC Antibody (Diagnostics)

2H16

1H17

1H17

.

Oncology Market Opportunities

Over 19 million new cancer cases are forecast to be diagnosed each year by 2025

Market shifting away from cytotoxic and anti-hormonal therapies toward targeted therapies that can block

the spread of cancer by interfering with specific molecules involved in tumor growth and progression

Biosceptre’s product candidates are considered targeted therapies

Sources: U.S. CDC, IMS Health, Inc. (2013), IMS Institute for Health Informatics, the U.S. NIH, and BioProcess

Technology Consultants, Inc. (graph)

Increase in Annual Sales of Leading Monoclonal Antibody

(mAb) Products from 2004 to 2013 In 2013, targeted therapies represented 46% of global

oncology sales, up from 11% a decade ago. In clinical

development, the oncology drug pipeline has expanded

by over 60% during the past decade, with approximately

90% of the focus on targeted agents.

The global cancer therapeutics market reported $100

billion in annual sales in 2014 and could reach $147

billion by 2018

Targeted therapies encompass the highest-selling class

of cancer therapeutics

Global mAb sales may reach approximately $94

billion by 2017 and nearly $125 billion by 2020

.

Potential Milestones

2H 2016 Private Round Fundraising (£25m)

2H 2016 Phase I Systemic Clinical Trials (antibody)

1H 2017 Phase I Systemic Clinical Trials (vaccine)

1H 2017 Start of 1 X Phase II Topical Clinical Trial

1H 2017 Initial Data from Clinical Trials

2H 2016 2 Material Transfer Agreements (MTA) with Pharma

2H 2016 1 Due Diligence

2016 3 Ongoing Pharma Discussions

2H 2016, 1H 2017 Potential for Multiple Licensing Events

COMMERCIAL

FINANCIAL

CLINICAL

• BIL03s (Biosceptre’s lead systemic antibody): seeking Australia’s Therapeutic Goods

Administration (TGA) approval and expects to begin a Phase I trial in 2016

• The BIL06v vaccine: seeking TGA approval and a Phase I trial is due to start in 2017

• Topical BIL010t product: stated an interest in out-licensing this product

.

Intellectual Property

• Biosceptre holds broad intellectual property

13 granted U.S. patents and a global portfolio with protection through 2032

IP protection on the nfP2X7 target until 2022 with additional protection covering

therapeutic intervention until at least 2035

17 additional published U.S. patent applications

• In parallel to its product development programs, Biosceptre has a pipeline of external

development programs through a series of collaborations, where the Company seeks out-

licensing agreements to develop cancer diagnostics and imaging technologies, as well as

veterinary programs, which can benefit from its proprietary position with nfP2X7.

.

To read the entire 52-page EIO on

Biosceptre International Ltd. (closely held)

or find information on other companies under

coverage, please visit www.crystalra.com.

.

Crystal Research Associates, LLC (www.crystalra.com) is an independent research firm that has

provided institutional-quality research on small- and mid-cap companies for the past decade. We

are led by veteran Wall Street sell-side analyst Jeffrey Kraws, who is well known by the

international financial media for his years of work on Wall Street and for providing consistent

award-winning analyses and developing long-term relationships on both the buy-side and sell-

side. He has been consistently ranked among the Top Ten Analysts for pharmaceutical stock

performance in the world for almost two decades as well as ranked as the Number One Stock

Picker in the world for pharmaceuticals by Starmine and for estimates from Zacks. Additionally,

Mr. Kraws has been 5-Star ranked for top biotechnology stock performance by Starmine.

About Us

Corporate Headquarters:

880 Third Avenue, 6th Floor

New York, NY 10022

Office: (212) 851-6685

Fax: (609) 395-9339Jeffrey J. Kraws,

Chief Executive OfficerKaren B. Goldfarb

President & COO

.

FACEBOOK — https://www.facebook.com/CrystalResearchAssociates

TWITTER — http://twitter.com/crystalresearch

YOUTUBE — https://www.youtube.com/user/crystalrsch

LINKEDIN — http://www.linkedin.com/company/crystal-research-associates

SLIDESHARE — http://www.slideshare.net/crystalresearchassociates

Connect with Crystal Research Associates